2019 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY conference
27th of Sept – 1st of Oct
Barcelona, Spain
ENYO Pharma will attend the ESMO conference in order to raise awareness of it novel, potent chemistry which induces Immunogenic Cell Death in multiple tumour types and inhibits tumor growth in animal models.
Read next in 'Events'
- The 2024 international workshop on Alport syndrome
- ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
- 6th CKD Summit – Chronic Kidney Disease Drug Development
- ASN Kidney Week
- Alport Connect 2023, the annual Alport syndrome patient and family meeting in US